About UNI HEALTH Company

Big Health International Group Holdings Limited (the “Company”, together with its subsidiaries, the “Group” and its subsidiaries (“Group”), stock code: 2211) targets huge market opportunities in the health field, strives to build an international big health brand operator, and has become a leading practitioner of the “Internet+Big Health” strategy, and an industry leader in developing the industrial chain ecosystem through finance and capital. The Company is one of the leading pharmaceutical retailers and distributors in the Northeast region of the People's Republic of China (“China”). The Group has an excellent pharmaceutical retail chain network in Northeast China and is one of the largest private pharmaceutical distributors in Northeast China. As of the date of this annual report, the Group has 203 retail pharmacies, mainly located in northeastern China. It has about 1,515 active distributors and 1,286 employees, and has set up four large-scale logistics storage and transportation centers in Shijiazhuang, Shenyang, Harbin and Jiamusi to establish a high-quality distribution system covering the whole country and the northeastern region of China. As a basic business segment, the Group's main business categories for pharmaceutical retail and distribution (including import and export trade) include prescription drugs, non-prescription medicines (proprietary Chinese medicines, chemical preparations, antibiotics, biochemicals), traditional Chinese medicine tablets, biological products, anabolic agents, peptide hormones, blood products, disinfectants, medical devices, family planning supplies (contraceptives and devices), pre-packaged food, dairy products (including infant formula), health food, health care products, cosmetic packaging and daily use department stores, etc. The Group continues to give full play to the core advantages of brand products, expand the scope of brand product cooperation, use business school curriculum training to provide more value-added services to employees, customers and consumers, and is committed to bringing more health products into the sales pipeline on a professional basis in drug retail and distribution, and implementing the concept of a big health industry. At the same time, the Group is actively expanding the upstream ecological chain, extending it to the field of construction of Chinese herbal medicine planting bases and production of vegetable capsules. The Group actively explores online pharmacies, cross-border e-commerce, influencer drainage and other “Internet +” fields, and promotes the “Professional +” concept, introduces the “Platform +” development concept, uses industry advantages to maintain the upstream and downstream ecosystems, cope with the “new normal” of the real economy, and take the lead in implementing industrial upgrading and digital transformation in the industry.